Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group
Andrea K Miyahira, Kenneth J Pienta, Michael J Morris, Neil H Bander, Richard P Baum, Wolfgang P Fendler, William Goeckeler, Michael A Gorin, Hartwig Hennekes, Martin G Pomper, Oliver Sartor, Scott T Tagawa, Scott Williams, Howard R Soule
The Prostate | WILEY | Published : 2018
K.J.P. and M.A.G. have received research support from Progenics Pharmaceuticals. M.J.M. is an uncompensated consultant to Endocyte, Progenics and Bayer, is a consultant to Advanced Accelerator Applications (AAA) and Blue Earth Diagnostics, and has received research funding through Memorial Sloan Kettering Cancer Center from Endocyte, Progenics and Bayer. N.H.B. is an inventor on patents that are assigned to Cornell Research Foundation (CRF) for the J591 antibody. N.H.B. is a consultant to and owns stock in BZL Biologics, the company to which the patents were licensed by CRF for further research and development. R.P.B. has served as consultant, advisor, and/or received honoraria from AAA, IPSEN Pharma, ITG Isotope Technologies Garching (ITG), and Telix Pharmaceuticals, and has received grant or research support from AAA and ITG. W.P.F. is an uncompensated consultant for Endocyte, and a consultant for Ipsen. W.-G. is an employee of Bayer Healthcare LLC., USA. H.H. is an employee and shareholder of Bayer AG, Germany. M.G.P. has licensed technology to and received research funding from Progenics Pharmaceuticals and AAA. O.S. has served as a consultant to Endocyte and AAA. S.T.T. has served as a consultant to Bayer and Endocyte and Weill Cornell Medicine has received research funding on his behalf for clinical trials from Bayer and Endocyte. S.W. has received travel support from and has served as an uncompensated consultant to Astellas.